BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:“Stratifying hepatic meta-inflammation: consequences for cancer 
 therapy”
DTSTART:20220317T121500
DTEND:20220317T133000
DTSTAMP:20260407T024622Z
UID:049d3a39f88dd98127e60347bae07d292b5332c4d63082b0c424bfe6
CATEGORIES:Conferences - Seminars
DESCRIPTION:Prof. Dr. Mathias HEIKENWÄLDER\nA Lola and John Grace Disting
 uished Lecture in Cancer Research\n\nMathias Heikenwälder - Department H\
 , German Cancer Research Center (DKFZ) in Heidelberg\, Germany.\n\nResearc
 h interests: Microbiology\, Cancer research\, Chronic inflammation\,Liver 
 carcinogenesis\, Immunotherapy\, Preclinical mouse models\n\nMathias Heike
 nwälder is an Austrian microbiologist and cancer researcher working in th
 e field of chronic inflammation and liver carcinogenesis.\nchronic inflamm
 ation and liver carcinogenesis. He investigates the molecular mechanisms t
 hat cause chronic inflammation\, tissue damage\, cancer and metastasis. Pr
 of. Heikenwälder is developing new models and therapeutic approaches in c
 lose cooperation with clinics.\n\nThe Heikenwälder laboratory aims at und
 erstanding the different immune signatures of chronic inflammatory human d
 iseases using relevant mouse models - with the final aim to generate model
 s of chronic inflammation potentially used for pre-clinical research. The 
 Heikenwälder laboratory focuses on comparative studies of human and anima
 l tissues\, recapitulating human disease on a histo-pathological and patho
 physiological level. The laboratory engages in classical molecular biology
  techniques complemented with sophisticated ways to receive as much inform
 ation from tissue samples through histology (e.g. light microscopy/ immune
  fluorescence/ FISH/ in situ hybridization)\, other in vivo imaging techni
 ques (e.g. MRI) as well as through FACS analyses for tissue homogenates. A
 t the same time\, the Heikenwälder laboratory is also interested in the s
 ystemic functional effects of pathologies and the interplay between severa
 l affected non-lymphoid tissues and the immune system.\nFinally\, testing 
 several therapeutic compounds in a single use but also combinatorial fashi
 on is one of the goals employing established and stratified pre-clinical m
 ouse models.\n\nProf. Heikenwälder publishes his work in high-ranking jou
 rnals and has established himself as an international leader in the field 
 of liver cancer. Mathias Heikenwälder is the third most frequently cited 
 German-speaking researcher in the field of cell biology in the last 5 year
 s and was one of the Highly Cited Researchers (Cross Fields) (Web of Scien
 ce Group) in 2019\, 2020 and 2021. Not only have his publications been wid
 ely cited by the research community\, but they have also shifted fatty liv
 er and liver cancer research in new directions - relevant to the day-to-da
 y management of patients with fatty liver or liver cancer. The current H-F
 actor of Mathias Heikenwälder is 75 (Web of Science)\, with 281 publicati
 ons listed in Pubmed.\n\n\n\n 
LOCATION:SV 1717 https://plan.epfl.ch/?room==SV%201717
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR